Form 4: Centessa Pharmaceuticals CBO Exercises Options, Sells Shares Under Pre-Arranged Plan

Centessa Pharmaceuticals plc's Chief Business Officer, Gregory M. Weinhoff, exercised stock options and simultaneously sold a portion of the resulting shares on July 25, 2025, under a Rule 10b5-1 trading plan.

Summary

• Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc, engaged in a transaction involving the company's Ordinary Shares on July 25, 2025.
• Weinhoff exercised options to acquire 10,000 Ordinary Shares at an exercise price of $3.85 per share.
• Concurrently, he sold 10,000 Ordinary Shares at a weighted average price of $15.5598 per share, with individual sales ranging from $15.315 to $15.67.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Weinhoff on May 22, 2024.
• Following these transactions, Weinhoff directly beneficially owns 122,279 Ordinary Shares and 55,000 share options.
• The Ordinary Shares may be represented by American Depositary Shares (ADSs), with each ADS currently representing one Ordinary Share.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive for the insider due to significant profit realized. For the company, it's largely neutral to slightly negative, as insider selling can sometimes be perceived negatively, but the use of a Rule 10b5-1 plan mitigates concerns about opportunistic selling based on new information. The transaction represents a routine management of equity compensation.

Positives

• The Chief Business Officer realized a significant profit by exercising options at $3.85 and selling shares at a weighted average price of $15.5598.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which indicates the transaction was not based on new, non-public information and is a common practice for executives managing their equity holdings.

Negatives

• The sale of shares by a Chief Business Officer, even under a 10b5-1 plan, could be perceived by some investors as a slight negative signal regarding insider confidence, although the pre-planned nature mitigates this concern.

Risks

• The filing itself does not detail company-specific risks; however, insider selling, even when pre-planned, can sometimes be misinterpreted by the market, potentially leading to short-term negative sentiment.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details an individual executive's equity transaction and does not provide broader industry context or trends. Such transactions are common for executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, as a means of managing personal finances and diversifying holdings.

Related Party Transactions

• The reported transactions are related party transactions as they involve an executive officer of the company exercising stock options and selling company shares.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a pre-arranged plan, might lead to minor short-term speculation, but the impact is likely minimal given the routine nature of such transactions and the relatively small number of shares sold compared to total outstanding shares.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (exercise of options and sale of shares) by a Chief Business Officer. While the insider realized a significant profit, the transaction was conducted under a Rule 10b5-1 plan, which suggests it was not based on new, non-public information. Such transactions are common for executives managing their personal finances and equity compensation. The filing does not provide new information about the company's operational performance, financial health, or strategic outlook that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this specific filing does not present a strong catalyst for either buying or selling the stock.

Keywords

Centessa Pharmaceuticals, CNTA, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, Share Sale, Executive Compensation, Biotechnology, Pharmaceuticals